[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nephrotic-syndrome-due-to-idiopathic-membranous-nephropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nephrotic-syndrome-due-to-idiopathic-membranous-nephropathy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632690","slit-abs-study-on-patients-with-autoimmune-podocytopathy-100632690",false,"NCT07516964","SLIT ABS: Study on Patients With Autoimmune Podocytopathy","Validation and Implementation of Diagnostic Techniques for the Detection of Circulating Factors in Patients With Autoimmune Podocytopathy","Inclusion Criteria:\n\n* Pediatric and adult patients with a diagnosis of podocytopathy\n* Patients with nephrotic syndrome and\u002For histological diagnosis of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), collapsing glomerulopathy (CG), or diffuse mesangial sclerosis (DMS)\n* Both newly diagnosed (incident) patients and patients already under follow-up at participating centers\n* Availability of clinical data from medical records (including paper and\u002For electronic records, laboratory reports, and discharge summaries)\n* Availability of biological samples (e.g., blood and\u002For renal biopsy), if collected as part of routine clinical care\n* Signed informed consent by the patient or legal guardian (and assent when applicable)\n\nExclusion Criteria:\n\n* Refusal or inability of the patient, parents, or legal guardian to provide informed consent\n* Lack of sufficient clinical data or unavailable biological samples required for the study","ALL","0 Years","99 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","Nephrotic syndrome is a kidney condition that mainly affects children and is characterized by high levels of protein in the urine, low levels of protein in the blood, and swelling. While many children respond well to steroid treatment, a large proportion experience relapses or become dependent on therapy. In some cases, the disease does not respond to standard treatments and may progress to chronic kidney disease.\n\nRecent research suggests that, in addition to genetic factors, immune system mechanisms may play a key role in the development and progression of nephrotic syndrome. In particular, some patients produce autoantibodies against nephrin, an essential protein of the kidney filtration barrier. These autoantibodies may be associated with disease activity and treatment response.\n\nThe aim of this study is to investigate the presence of anti-nephrin autoantibodies in children with nephrotic syndrome and to better understand their role in disease mechanisms and clinical outcomes.The study will also explore the presence of other autoantibodies targeting components of the glomerular filtration barrier. The study will use advanced laboratory techniques, including blood tests and detailed analysis of kidney biopsy samples, to identify these antibodies and their relationship with kidney structure and function.\n\nBy integrating laboratory findings with clinical data, this study aims to improve the understanding of nephrotic syndrome and support the development of more personalized diagnostic and therapeutic strategies, with the goal of improving patient outcomes and reducing unnecessary or ineffective treatments.",[27,28,29,30],"Nephrotic Syndrome With Edema (Diagnosis)","Minimal Change Nephrotic Syndrome","Focal Segmental Glomerulosclerosis (FSGS)","Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy","RECRUITING","2026-04-01",{"date":34,"type":35},"2026-04-08","ACTUAL",{"date":37,"type":35},"2025-06-10",{"date":39,"type":21},"2036-10",{"name":41,"class":42},"Meyer Children's Hospital IRCCS","OTHER",14,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100397568","phase-2-a-study-of-the-safety-tolerability-pharmacokinetics-and-efficacy-of-treatment-with-ap1189-in-patients-with-imn-and-severe-proteinuria-100397568","NCT04456816","A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria","An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe Proteinuria","Inclusion Criteria:\n\n* Written informed consent has been obtained prior to initiating any study-specific procedures\n* Male and female subjects, 18 to 85 years of age diagnosed with iMN within 6 months prior to inclusion\n* Diagnosed as anti-PLA2-Receptor positive by local laboratory within 6 months prior to inclusion\n* Severe proteinuria defined by a U-protein\u002Fcreatinine ratio \\>3.0 g\u002Fg and\u002For U-albumin\u002Fcreatinine ratio \\>2.0 g\u002Fg and a P-albumin below the lower normal limit\n* eGFR \\> 30 ml\u002Fmin\u002F1.73m2\n* Treated with ACE- inhibitors or angiotensin II receptor blocker for a minimum of 1 months with a stable systemic arterial blood pressure OR treatment with ACE inhibitors and\u002For angiotensin receptor blocker was excluded or discontinued due to hypotension, intolerance or other side effect\n\nOnly Denmark and Norway:\n\n* Females of child-bearing potential using reliable means of contraception or are post-menopausal\n* Females of childbearing potential with negative pregnancy test at screening and baseline\n\nOnly Sweden:\n\n* Post-menopausal women or women who are surgically sterilized.\n\nExclusion Criteria:\n\n* Participation in any other study involving investigational drug(s) during the study and within 4 weeks prior to study entry\n* Clinicial findings that in the opinion of the investigator would suggest condition(s) other than iMN as a major cause of severe proteinuria\n* Major surgery within 8 weeks prior to screening or planned surgery within 1 month following randomization\n* Blood pressure with systolic pressure above 160 mmHg and\u002For diastolic pressure above 100 mmHg despite antihypertensive treatment will in all cases be considered \"uncontrolled\"\n* Treated with systemic corticosteroids, or other immune suppressive, or immune modulating compounds within 4 weeks prior to screening and during the entire treatment period and until the final visit\n* Treated with rituximab within 12 months of screening\n* Evidence of active malignant disease\n* Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids\n* Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disease\n* Pregnant women or nursing mothers\n* History of alcohol, drug, or chemical abuse within the 6 months prior to screening\n* Any condition that in the view of the investigator would suggest that the patient is unable to comply with study protocol and procedures\n\nOnly Sweden:\n\n* Females of child-bearing potential.","18 Years","85 Years",{"count":54,"type":21},23,[56],"PHASE2","This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study with repeated doses of AP1189. The study population will consist of patients with idiopathic membranous nephropathy (iMN) and severe proteinuria who are on ACE inhibitor or angiotensin II receptor blocker treatment.",[30,59],"Severe Proteinuria Due to Idiopathic Membranous Nephropathy","2026-03-04",{"date":62,"type":35},"2026-03-06",{"date":64,"type":35},"2020-08-31",{"date":66,"type":21},"2026-06-30",{"name":68,"class":69},"SynAct Pharma Aps","INDUSTRY",1]